Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the ten research firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $50.40.
TWST has been the topic of several research reports. Robert W. Baird cut their price target on shares of Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating on the stock in a report on Tuesday, May 6th. Guggenheim reaffirmed a "buy" rating and set a $50.00 price objective on shares of Twist Bioscience in a research note on Tuesday, May 6th. Barclays dropped their price objective on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating on the stock in a research note on Thursday, April 10th. The Goldman Sachs Group dropped their price objective on shares of Twist Bioscience from $55.00 to $48.00 and set a "buy" rating on the stock in a research note on Tuesday, May 6th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating on the stock in a research note on Tuesday, May 6th.
Get Our Latest Research Report on TWST
Twist Bioscience Stock Performance
NASDAQ:TWST traded up $0.43 during midday trading on Wednesday, hitting $38.11. The company's stock had a trading volume of 445,333 shares, compared to its average volume of 966,972. Twist Bioscience has a fifty-two week low of $27.12 and a fifty-two week high of $60.90. The firm's 50 day moving average is $33.49 and its 200-day moving average is $40.19. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.51 and a quick ratio of 4.24. The firm has a market cap of $2.28 billion, a P/E ratio of -11.73 and a beta of 2.41.
Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.10). Twist Bioscience had a negative return on equity of 33.48% and a negative net margin of 54.98%. The business had revenue of $92.79 million during the quarter, compared to analyst estimates of $92.00 million. Equities analysts anticipate that Twist Bioscience will post -2.12 earnings per share for the current fiscal year.
Insider Activity
In other news, CEO Emily M. Leproust sold 5,042 shares of the stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $37.65, for a total transaction of $189,831.30. Following the transaction, the chief executive officer owned 655,432 shares in the company, valued at $24,677,014.80. This trade represents a 0.76% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Dennis Cho sold 689 shares of the stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $37.65, for a total value of $25,940.85. Following the transaction, the insider owned 110,849 shares in the company, valued at $4,173,464.85. This trade represents a 0.62% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 21,911 shares of company stock worth $761,826. Insiders own 3.01% of the company's stock.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Twist Bioscience by 186.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,442,262 shares of the company's stock valued at $95,883,000 after purchasing an additional 1,588,587 shares in the last quarter. First Light Asset Management LLC purchased a new position in Twist Bioscience in the 4th quarter valued at $56,984,000. EdgePoint Investment Group Inc. purchased a new position in Twist Bioscience in the 1st quarter valued at $43,705,000. Marshall Wace LLP lifted its holdings in Twist Bioscience by 15,927.8% in the 4th quarter. Marshall Wace LLP now owns 846,107 shares of the company's stock valued at $39,319,000 after purchasing an additional 840,828 shares in the last quarter. Finally, Nuveen LLC purchased a new position in Twist Bioscience in the 1st quarter valued at $31,960,000.
Twist Bioscience Company Profile
(
Get Free ReportTwist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
Recommended Stories

Before you consider Twist Bioscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Twist Bioscience wasn't on the list.
While Twist Bioscience currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.